Skip to content
Vivimed Labs logo

Vivimed Labs

VIVIMEDLAB NSE
₹5.64 down 0.11 (1.91%)
Market Cap
₹46.76 Cr

Vivimed Labs (VIVIMEDLAB) share price was ₹5.75 at the 28 Oct 2026 close; market capitalisation ₹47.68 Cr; sector Healthcare. In the Mar 2026 quarter, revenue fell 53.1% year on year to ₹12.0 Cr and net profit was −₹147 Cr, against −₹6 Cr a year earlier (compared with Mar 2025). Promoters held 7.57% of Vivimed Labs in Mar 2026, down 0.20 percentage points from Dec 2025. Its Tapetide Score is 41/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹5.75 −20.85 −78.38% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹46.76 Cr
EBITDA
−₹152 Cr
Return on Equity
90.88%
Debt to Equity
0
Book Value
−₹29.98
EPS (TTM)
−₹21.28
52W High
₹29.40
52W Low
₹4.75

Price-based figures as of 29 Oct 2026, 10:30 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,765.9035.034,23,699 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,653.5087.622,56,270 Cr15.290.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,595.2072.141,74,787 Cr9.510.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,190.10108.211,18,334 Cr22.330.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,181.6026.291,17,865 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,337.3034.641,11,622 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,363.1032.661,10,119 Cr3.110.96%11.21%14.88%28,589 Cr3,356 Cr
Vivimed Labs (this company)
₹5.64—47 Cr—0.00%90.88%-5.64%76 Cr-176 Cr
Median 8 companies₹1,564.5035.031,18,099 Cr5.070.47%14.56%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

41 Weak
Overall score

Data confidence 84/100

Category scores

Quality Poor 24
Returns, margins, earnings quality 22% weight
Valuation Strong 72
Cheap vs sector & own history 24% weight
Growth Poor 5
Sales & profit trajectory 9% weight
Financial Health Poor 10
Solvency, leverage, coverage 9% weight
Momentum Poor 31
Trend strength, vol-adjusted 12% weight
Ownership Average 49
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

6
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -39.5% over past five years.
  • Promoter holding is low: 7.57%
  • Contingent liabilities of Rs.183 Cr.
  • Company has high debtors of 236 days.
  • Promoter holding has decreased over last 3 years: -13.4%

Technical Indicators

Oscillators

Bullish

Bearish
2
Neutral
3
Bullish
4

Overall

Bearish

Bearish
12
Neutral
3
Bullish
4

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-41.97% lower than 3Y

change over 1 year

Net Income Growth
451% higher than 3Y

change over 1 year

Cash Flow Change
92.71%

change over 1 year

Quarterly Results

Particulars Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
37
35
34
41
39
29
25
37
26
21
21
16
12
Expenses
201
36
40
40
67
40
25
35
28
22
22
27
152
Operating Profit
-164
0
-6
1
-28
-11
-1
1
-2
0
-1
-11
-140
OPM %
-444%
-0.9%
-18%
3.1%
-74%
-37%
-2.6%
2.9%
-10%
-1.3%
-4.6%
-68%
-1169%
Other Income
1
0
2
0
8
0
0
0
4
0
0
0
6
Interest
9
11
12
13
-33
0
0
0
2
1
2
1
1
Depreciation
96
5
5
5
6
4
4
7
6
5
5
5
12
PBT
-268
-16
-20
-17
7
-15
-5
-6
-5
-5
-7
-17
-147
Tax %
-1%
0%
0%
-3%
21%
0%
0%
0%
2%
0%
0%
0%
0%
Net Profit
-266
-16
-20
-16
5
-15
-5
-6
-6
-5
-7
-17
-147
EPS (₹)
-32.08
-1.88
-2.45
-1.94
0.63
-1.84
-0.62
-0.72
-0.68
-0.66
-0.88
-2
-17.74
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
1,380
1,346
1,462
1,186
1,315
1,059
861
237
187
149
116
70
Expenses
1,156
1,111
1,057
971
1,135
1,049
830
245
374
182
129
222
Operating Profit
224
234
404
215
180
10
32
-8
-187
-33
-13
-152
OPM %
16%
17%
28%
18%
14%
1%
3.7%
-3.3%
-100%
-22%
-11%
-218%
Other Income
6
11
8
10
23
8
10
1
1
10
4
6
Interest
86
84
68
82
70
61
56
40
36
3
3
4
Depreciation
66
61
58
56
67
67
56
18
108
20
20
26
PBT
78
100
286
86
66
-109
-70
-65
-331
-46
-32
-176
Tax %
7%
16%
25%
11%
13%
0%
3%
4%
-1%
-1%
0%
0%
Net Profit
72
84
214
76
57
-109
-72
-68
-329
-45
-32
-176
EPS (₹)
8.9
10.33
26.41
9.44
6.95
-13.16
-8.67
-8.16
-39.62
-5.48
-3.85
-21.28
Div. Payout %
0%
0%
2%
4%
0%
0%
0%
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
16
17
17
17
17
17
17
17
17
17
Reserves
479
505
718
885
602
493
415
348
23
-22
-52
-227
Borrowings
1,076
1,015
1,011
1,149
1,280
1,268
326
359
379
377
376
397
Other Liabilities
327
519
317
343
431
432
532
543
658
579
580
567
Total Liabilities
1,898
2,055
2,062
2,394
2,329
2,210
1,289
1,266
1,076
950
921
753
Fixed Assets
813
814
879
1,035
965
1,045
502
520
436
418
408
386
CWIP
90
94
76
65
122
89
60
40
21
21
17
18
Investments
3
3
3
3
3
86
199
199
199
168
168
181
Other Assets
992
1,144
1,104
1,290
1,239
990
529
507
421
343
328
170
Total Assets
1,898
2,055
2,062
2,394
2,329
2,210
1,289
1,266
1,076
950
921
753
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
140
154
58
21
422
80
567
28
35
-24
-2
8
Investing
-107
-190
-68
-164
-89
-196
404
-16
-5
28
-5
-1
Financing
-42
41
35
186
-338
72
-1,015
-10
-34
-6
5
-6
Net Cash Flow
-8
4
25
44
-5
-44
-44
1
-3
-2
-1
1
Free Cash Flow
16
95
-11
-142
333
-33
1,084
11
30
-26
-6
7
CFO/OP
63
66
23
30
243
972
1,720
-352
-19
73
13
-5
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
87
88
50
85
99
86
46
134
145
203
233
236
Inventory Days
244
294
329
411
397
396
263
573
216
327
358
63
Days Payable
107
98
122
154
207
179
35
100
74
225
240
263
Cash Conversion Cycle
224
285
258
342
288
303
274
607
286
305
351
36
Working Capital Days
43
58
55
121
68
216
77
195
-15
-171
-255
-1,468
ROCE %
11%
12%
22%
9%
7%
-3%
-1%
-3%
-52%
-11%
-8%
-65%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vivimed Labs insights

69 extracted metrics + investor summaries across FY10–FY26.

Shareholding Pattern

Govt.0.12%Public68.75%FIIs1.64%Promot.7.57%Others21.91%As ofMar 2026
15.18% of promoter holding pledged as of Mar 2026

Documents

1
Concall - Aug 2019 Aug 2019
2
Concall - Mar 2019 Mar 2019
3
Concall - Nov 2018 Nov 2018
4
Concall - Aug 2018 Aug 2018
5
Concall - Jun 2018 Jun 2018

Frequently Asked Questions about Vivimed Labs

What does Vivimed Labs Ltd do?
Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.[1][2]
Where is Vivimed Labs Ltd (VIVIMEDLAB) listed?
Vivimed Labs Ltd trades as VIVIMEDLAB on the NSE and under code 532660 on the BSE.
Which sector does Vivimed Labs Ltd belong to?
Vivimed Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Vivimed Labs Ltd?
Vivimed Labs Ltd has a market capitalisation of ₹46.76 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Vivimed Labs Ltd?
Over the last 52 weeks Vivimed Labs Ltd has traded between ₹4.75 and ₹29.4 as of 29 Oct 2026.
What is the Return on Equity (ROE) of Vivimed Labs Ltd?
Vivimed Labs Ltd reported a return on equity of 90.88%. Its debt-to-equity ratio is 0.00.

Company Information

Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.[1][2]

Website vivimedlabs.com
CEO Dr. Manohar Rao Varalwar
Employees 586
Listed 2005-08-17
Face Value ₹ 2
Shares Outstanding 8,29,13,915

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VIVIMEDLAB.md for Vivimed Labs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month